Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Market Ranbaxy Products in China
April 24, 2012
- Bayer Yakuhin to Set Up Committee to Promote Proper Use of Xarelto
April 23, 2012
- TPU Withdraws NDA for Aricept Transdermal Patch: Eisai
April 23, 2012
- Terapia Ranbaxy to Launch Fixed Dose Combination of Olmesartan, Amlodipine in Romania
April 23, 2012
- Daiichi Sankyo Looking to Establish “Base Treatment” Position for Memary
April 23, 2012
- Mylan, Fuso Settle with Kureha in Kremezin Generic Patent Litigation
April 20, 2012
- Kaketsuken and Astellas Enter Sales and Marketing Agreement for Inactivated Polio Combination Vaccine
April 20, 2012
- Meiji Seika Pharma Discontinues Development of Hepatitis C Drug
April 20, 2012
- Nexium No. 1 in Call Frequency in HP Market for 2nd Month in a Row: Rep Track Survey
April 20, 2012
- Bayer Yakuhin Launches Oral Factor Xa Inhibitor Xarelto
April 19, 2012
- Ono’s MS Treatment ONO-4641 Meets Primary Endpoint in PII Study
April 19, 2012
- Novartis Files for Add’l Indication of PAH for Glivec
April 19, 2012
- Takeda to Differentiate New ARB Azilva Stressing Its Strong Hypotensive Effects
April 19, 2012
- JPWA, NPhA Agree to 6-Month Limit on Price Negotiations; Wholesalers’ Resolution to Be Tested for 3rd Time
April 19, 2012
- Teva Pharma Japan Aims at Early Launch of Biosimilars Marketed Overseas in Japan: President Shimada
April 18, 2012
- Dainippon Sumitomo Pharma Files for Supplemental Approval of Surepost in Combination Therapy with Biguanides and with Thiazolidinediones
April 18, 2012
- Hiring of New Pharmacists Sluggish Due to Decreasing Numbers of Applicants, Tough Competition: Major Dispensing Pharmacies
April 18, 2012
- Eisai Launches Insomnia Treatment Lunesta
April 18, 2012
- Daiichi Sankyo Launches Ranmark for Treatment of Bone Lesions Associated with Cancer; AZ to Copromote Product
April 18, 2012
- Eli Lilly Japan Pinning New Hopes on Solanezumab; Will the Introduction of Medicoeconomic Assessments Help?
April 18, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…